ࡱ>  xbjbj44 VV9o>>+++++4+++h4,d-+ܯR.@1(h1h1h1W2 89[]]]]]]$.j+:W2W2::++h1h1CCC:F+h1+h1[C:[CCb$;h1}$\:VG0ܯBJ:fJ;;J+۬l::C:::::G?:::ܯ::::J:::::::::> ^*: Please delete these template instructions. TEMPLATE INSTRUCTIONS Purpose of a Protocol: A protocol is the document that a study team uses to conduct the study. The protocol contains the methodology to be employed and contains instructions for all of the execution steps. It is a guide for the research team to reference and follow over time and ensures that the IRB approved version of the study is implemented. When the study is complete, the protocol will aid in writing-up the study to publish and offer details for repeatability. Minimal Risk - 406.102 (i) - means that the magnitude and probability of harms or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. See the FDA definition at:  HYPERLINK "http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=50.3&SearchTerm=minimal%20risk" http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=50.3&SearchTerm=minimal%20risk or the Common Rule definition at  HYPERLINK "http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html#46.102" http://www.hhs.gov/ohrp/humanparticipants/guidance/45cfr46.html#46.102 Further Guidance on what categories of research would meet minimal risk definition can be found at OHRP:  HYPERLINK "http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html#46.110" http://www.hhs.gov/ohrp/humanparticipants/guidance/45cfr46.html#46.110 and at the FDA for FDA regulated or sponsored studies:  HYPERLINK "http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=56.110&SearchTerm=minimal%20risk" http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=56.110&SearchTerm=minimal%20risk Minimal Risk studies, while simpler than studies of greater than minimal risk, still have regulatory obligations. A well written protocol is the prologue to well conducted research and as such, a minimal risk protocol should include, at a minimum, sections on brief background/rationale, study objectives, expected risks/benefits, eligibility, participant enrollment, study design/procedures, data collection and management, data analysis, quality control and quality assurance, statistical considerations, informed consent, privacy issues, unanticipated problems, and references. The following pages describe a template suitable for use. DO NOT use this template if your research involves the use of a drug, biologic, vaccine or medical device; use the medical template located on the IRB website:  HYPERLINK "http://www.stjoesannarbor.org/IRBForms" http://www.stjoesannarbor.org/IRBForms Delete these template instructions. Study Title Version # Date NOTE: Using a date and version number is very important to track so that the current version is being used by the study team and is same version that is on file with the IRB. Change these each time you submit protocol changes to the IRB Principal Investigator: Department: Funding Mechanism: (e.g., SJMHS Research Committee, grant, etc.) Institution(s)/Hospital locations: (indicate all locations involved) NOTE: If you are using this template it is assumed that this is a Principal Investigator led study. IF you are collaborating with other external institutions (e.g. external to SJMHS) then there are other documents that may be required, such as a clinical trial agreement, contract, memorandum of understanding, data/specimen transfer agreement, or some other legal document that specifies the operative tactics, such as defined roles/responsibilities, financial relationships, publication rights, budgetary considerations, study monitoring requirements, billing issues and the like. Sub-Investigators: (Optional) Table of Contents  TOC \o "1-3" \h \z \t "SchemaTitle,1" HYPERLINK \l "_Toc243298794"  HYPERLINK \l "_Toc243298795"Table of Contents  PAGEREF _Toc243298795 \h 3 HYPERLINK \l "_Toc243298797"List of Abbreviations  PAGEREF _Toc243298797 \h 4 Executive Summary.... 4 HYPERLINK \l "_Toc243298798"1 Background and Scientific Rationale  PAGEREF _Toc243298798 \h 5 HYPERLINK \l "_Toc243298799"2 Objectives  PAGEREF _Toc243298799 \h 5 HYPERLINK \l "_Toc243298800"3 Anticipated Risks and Benefits  PAGEREF _Toc243298800 \h 5 HYPERLINK \l "_Toc243298801"4 Eligibility  PAGEREF _Toc243298801 \h 5 HYPERLINK \l "_Toc243298802"5 Participant Enrollment and/or Screening  PAGEREF _Toc243298802 \h 6 HYPERLINK \l "_Toc243298803"6 Study Design and Methods  PAGEREF _Toc243298803 \h 7 HYPERLINK \l "_Toc243298805"7 Data Analysis and Statistical Considerations 9 8 Data Confidentiality and Storage ...10 9 Data Safety and Monitoring Plan ...11 HYPERLINK \l "_Toc243298808"10 Regulatory Requirements  PAGEREF _Toc243298808 \h 11 Informed Consent ............12 Participant Privacy .......14 HYPERLINK \l "_Toc243298810"HIPAA ....14 Unanticipated Problems and Adverse Events..14 Conflict of Interest .......15 12 HYPERLINK \l "_Toc243298812"Limitations and Assumptions... .....15  15 References.15 14 HYPERLINK \l "_Toc243298813"Appendices  PAGEREF _Toc243298813 \h 17  List of Abbreviations  Executive Summary Summary of Objectives: Summary of Study Design: Outcome measures: Statistical Summary Plan (including sample size rationale and justification): 1 Background and Scientific Rationale Describe the research problem and provide rationale for the research. Describe the significance of the problem being studied. Address whether the research is expected to contribute new information to the field and whether the intervention or hypothesis has been tested before. Discuss briefly any literature important to the study, include the cite, and include full references in Section 12. Briefly summarize investigators prior experience and/or history relevant to the research. Identify the funding sources State what regulatory authority the study will fall under, i.e. OHRP, FDA or other regulatory oversight body State whether research is a prospective intervention/data collection or if the data already exists at the time of study commencement (retrospective). This may be repeated later in the methodology section in more detail. 2 Objectives Specify primary hypothesis. Specify secondary hypothesis(es), if indicated Specify objectives or specific aims. 3 ANTICIPATED Risks and Benefits Include all expected risks and all benefits to participants and/or society. Address how risks will be minimized Address how benefits will be maximized. Justify the level or degree of risks to the participants. NOTE: This information will be used to determine whether an event is expected and therefore not an unanticipated problem requiring reporting. 4 Eligibility Identify the participant/donor populations- include all groups/cohorts that will be studied. List inclusion and exclusion criteria. Indicate all the sources of participants/donors/records. Describe all vulnerable populations and/or any excluded populations. Specifically include a justification for the use of a vulnerable group (as opposed to a group that is healthy and not vulnerable). For example: employees, minors, persons with diminished capacity, very elderly, low income, under educated, etc. 5 Participant Enrollment and OR SCREENING Describe how the participants will be identified this applies to all studies; through screening in the record, through Quality Institute running a search in the medical record, etc. This will help the IRB determine the applicable research regulations for what you will be doing. Provide a detailed description of the need to access medical records for the purposes of screening or contacting: describe in detail the minimum necessary variables that will be obtained. Describe screening and/or enrollment processes: chart review studies, specimen studies, as well as interventional studies. State how and where the eligibility and exclusion criteria will each be documented for each potential participant. State how you will procure study data for screening. State if the data already exists or if it will be prospectively collected. Describe who will access the records needed for the study (roles). Describe from where participants will be recruited and any advertising or recruitment materials that will be used. All material to be given to prospective participants must be located in appendixes or attachments and all materials require prior IRB review and approval. Describe what happens with screen failures and any data obtained from screen failures, as applicable. Describe the confidentiality procedures that will be used for screening purposes. Submit or include as an appendix all screening tools. HIPAA regulations apply to the screening process if it involves review of medical/health/mental health records. Investigators will need to obtain prospective HIPAA authorization for the screening activities or apply for a waiver of HIPAA authorization, as applicable, depending on the nature of the study. If this is a study under OHRP purview, then a waiver of consent will need to be obtained to screen in the medical or other record for eligibility criteria. If a screening script for research will be used with potential participants, then attach the script. If such screening activities will take place prior to the prospective participant providing informed consent for participation in the research, the investigator will need to obtain a waiver of documentation of informed consent (i.e. signed consent) for screening activities with prospective participants. 6 Study Design and METHODS Describe the study design and methods. The description should be capable of meeting the study objectives. Provide a thorough description of all study procedures, assessments and participant activities in a logical and sequential format. Describe the determination of the number of variables needed for sample size rationale/justification. Precisely define the outcome variables that align with each aim or hypothesis. State how the outcome variables will be measured. If assessments occur over time, provide a table to show when assessments will occur relative to enrollment. Include the expected duration of the study and of participant participation. Include a flow diagram for clarity. Describe data collection tools, specimens, surveys and study instruments. Describe the roles and responsibilities of the research team members, briefly how they are qualified to perform the role, and include a tracking sheet to document these roles with each member. Include any written materials as Appendices that will be part of the research, such as questionnaires, surveys, data collection tools, scripts etc. Describe any literacy or foreign language concerns or accommodations. Describe how missing or incomplete information will be handled in analysis. As appropriate, describe plans to address inter-rater reliability. For particular types of studies, the following information should be considered and provided: For Specimen Collection Studies/Data Repositories/Banks Describe the specimens to be collected. Describe aliquoting and any plans for retention of specimens. Describe tracking and labeling system. If specimens will be banked for future use, describe what the process is for providing investigators with access to the bank. Describe how such requests and access with be tracked. Describe how specimens will be analyzed (type and state of development of assay, controls, etc.) NOTE: IF you intend on collaborating with other institutions where SJMHS will be supplying tissues/specimens/data to another bank/institution or vice versa, you will have to have a legally authorized contract/agreement drawn as well as a Materials Transfer Agreement/Data Use Agreement signed by authorized individuals from each institution. These documents are not required to be submitted to the IRB BUT, you should consider drafting these agreements prior to seeking IRB approval. Consent Considerations: Informed consent must allow participants to determine future use, other use beside specific research and use for genomic projects. Provisions must be made to allow for withdrawal of a specimen if a participant withdraws consent and the link is still maintained. Future studies using banked specimens must be prospectively reviewed and approved by the IRB before such studies can proceed. Behavioral Intervention Studies Describe all of the steps for the implementation of the intervention and in what settings it will be used. Include the roles of who will implement the steps. Describe how fidelity of the intervention process will be assured. Describe how competence or compliance with fidelity will be demonstrated and maintained. Describe what will be done with any audio or video tapes after the study is completed. This information must also appear in the consent document. Consent Considerations: Describe in the informed consent what will be done with any audio, image, video or digital records after the study is completed. State when these recordings will be destroyed in the consent. For Studies that Collect Existing or Prospective Data Describe the source of the information. Describe whether data are to be collected prospectively (come into existence after IRB approval). Describe the time period of the medical information under review. This is the dates of the records, not the dates that you will actually look at the records. Provide a complete list of all the variables to be collected, their definitions and location in source documents. Consent Considerations: See the IRB SharePoint website for more consent guidance:  HYPERLINK "http://sjmhsmi.che.org/sjmaa/dept/IRB/Informed%20Consent%20and%20HIPAA%20Tools/Forms/Library.aspx" http://sjmhsmi.che.org/sjmaa/dept/IRB/Informed%20Consent%20and%20HIPAA%20Tools/Forms/Library.aspx Include plans in the regulatory section below, to request a waiver of consent and a waiver of HIPAA for retrospective studies where the data already exists at the time of the study approval. Focus Group Requirements Describe qualifications of facilitator or individual supervising facilitation. Expectations include: Prior experience facilitating groups Adequate knowledge of the topic Understands the purpose of group Provide script or discussion questions that will be used in focus group. Describe any literacy or foreign language concerns or accommodations. Describe how information will be captured. Describe how information from focus group will be presented and used. How will focus group responses be summarized and integrated? How will contradictory responses be handled? Will there be thematic or qualitative coding of transcribed discussions? Will focus group responses be used to guide the development of education materials, measures, interventions or other research procedures, publication, or inform study design? Describe whether information drawn from focus group will be shared with group participants. Describe what will be done with any audio, image, video or digital records after the study is completed. Consent Considerations: Describe in informed consent document what will be done with any audio, image, video or digital records after the study is completed. State when these recordings will be destroyed in the consent. Survey studies Describe survey methodology. Describe development or selection of questionnaire. Describe any literacy or foreign language concerns or accommodations. Indicate whether or not the questionnaire is validated. Describe how questionnaire will be tested (e.g., piloted, if applicable.) Consent Considerations: Include plans to either consent, waive documentation of consent, or to request a waiver of consent. 7 Data Analysis AND STATISTICAL CONSIDERATIONS Arrangements: Describe arrangements for data analysis including the name and address of the data analyst, statistician or theme analyzers. Indicate whether this person(s) will receive data that has any identifiable information (not just PHI) or not. If the person receives identifiable information then he/she must be part of the research team. As applicable: Describe the methods used to deliver data to the external entity and describe what information will be given (describe if data will be stripped of all identifiers or not). If an external entity will be performing data analyses: then additional agreements may be required such as a Business Associate Agreement, or Data Use Agreement. Statistics: Qualitative methods: describe how the data will be examined and the type of qualitative analysis in detail. Describe the method for developing themes. Disregard the rest of this section. Quantitative methods: Describe how the data will be examined and the type of statistical analyses that will be used to answer the objectives and test the hypotheses. Describe how missing data and outliers will be handled. Provide a sample size justification or description of a sample size calculation. Include methods and assumptions such as expected effect size, loss to follow-up, as appropriate. 8 Data Confidentiality and storage Describe who will collect and have access to the data/specimen repository/completed surveys/focus group results. Describe how data will be maintained in a secure manner and the exact location it will be kept. If being kept on a secure server, state who owns the server. State security of physical location if keeping hard copies/specimens. Information that has any identifiable information should not be kept on a laptop or mobile device. Describe the process for maintaining confidentiality of the data/materials/specimens/study results. Describe how long will the information/data/survey/focus group results/specimens be retained. Clearly state whether or not a link to any identifiers will be kept. Provide the justification for retaining a link for a prolonged period of time. Describe de-identification methods to be employed and location of key linking the data to the participant, as applicable. As applicable: Describe source documents and how data will be collected from source documents and incorporated into the database or specimen repository. Describe plans for destroying the data or other handling once the study is completed. Describe specimens that will be collected, how they will be procured and where the specimens will be stored and who will be responsible for care of specimens during storage. If biological samples will be procured and sent to another location then an Agreement For Transfer Of Human Specimens and/or Coded Private Information to an Outside Researcher must be drafted and signed by authorized individuals at each institution/location (consult Legal for review and signing) 9 DATA AND Safety Monitoring Plan Describe how the research team will ensure adherence to the protocol. State frequency and methods used to document adherence and process for identifying when an amendment to the protocol needs to be submitted to the IRB. Please note, protocol adherence is a problematic finding sometimes noted after an audit. Describe how data will be evaluated for accuracy in relation to source documents, as applicable. Describe either a) the use of a Data and Safety Monitoring Board or other body or b) the use of a Data and Safety Monitoring Plan. Describe who is responsible for the evaluation of data quality and how frequently this will be done. Describe the process to be used to determine unexpected/untoward events, determination of harm, or protocol deviations and determination of which events need to be reported immediately to the sponsor and/or the IRB. Describe the methods to be used to document the data monitoring activity. 10 Regulatory Requirements informed consent Interventional portion of study Describe either: a) how informed consent will be obtained and/or assent, who will obtain it, and if documentation will be gained or if a request for waiver of documentation will be sought; or b) the rationale for requesting a waiver of consent and/or waiver of assent. If waiving consent, skip to next section. If obtaining consent: If applicable, describe how participants will have an opportunity to privately ask questions and receive answers. If applicable, identify the time that will be used when they are not under duress or under undue influence that will allow sufficient time and opportunity to ask questions and to consider whether or not to participate in the research before agreeing to participate. If research involves minors, describe assent process, as applicable. If research seeks to prospectively recruit those with diminished capacity to consent and understand the study, describe the steps that will be taken to assure capacity to consent and whether participants will be re-consented, and if so, at what points. If research seeks to prospectively recruit participants that do not speak English, describe process for using the "short form" consent document and/or plans to translate the consent and all participant materials to the language understood by the participants. Describe process for documenting that the consent process took place. State location of this documentation. Include informed consent as an appendix. Informed consent must include the following (unless an alternation of consent is obtained for one or more of the required elements): Written in laymans language and understandable to the persons being asked to participate. A clear statement that the study involves research. An explanation of the purposes of the research. The expected duration of the research participants participation. A description of the procedures to be followed. Identification of any procedures which are experimental. A description of any reasonably foreseeable risks or discomforts. If there are none, this should be stated. A description of any benefits to the participant or to others that may reasonably be expected from the research. If there are none, this should be stated. A description of alternatives to participation in the research study. A statement describing the extent, if any, to which confidentiality of records identifying the participant will be maintained. An explanation of whom to contact for answers to pertinent questions about the research and the research participants rights, and whom to contact in the event of research-related injury to the participant. A statement that participation is voluntary, refusal to participate will involve no penalty or loss of benefits to which the participant is otherwise entitled and the participant may discontinue participation at any time without penalty or loss of benefits to which the participant is otherwise entitled. Additional elements, as appropriate: A statement that the particular treatment or procedure may involve risks to the participant which are currently unforeseeable. Anticipated circumstances under which the participants participation may be terminated by the investigator without regard to the participants consent. Any additional costs to the participant that may result from participation in the research. The consequences of the participants decision to withdraw from the research and procedures for orderly termination of participation by the participant. A statement that significant new findings developed during the course of the research, which may relate to the participants willingness to continue participation, will be provided to the participant. The approximate number of study participants needed and location (s) of study conduct. PARTICIPANT PRIVACY Describe how the participants privacy will be maintained. Provide justification for use of personally identifiable data or private health information (PHI). Describe whether a Certificate of Confidentiality issued by NIH will be pursued by the investigator after IRB approval. A Certificate of Confidentiality protects investigators and institutions from being legally compelled to release information that could be used to identify research study participants where the disclosure could have adverse consequences for participants or damage: financial standing, employability, insurability, or reputation. Sought through NIH and typically for research involving the study of illegal behaviors, lawsuits, sexual preferences, psychological well-being, deviate behaviors, and genetic information; to list a few broad examples. See NIH for application:  HYPERLINK "https://grants.nih.gov/grants/policy/coc/appl_intramural.htm" https://grants.nih.gov/grants/policy/coc/appl_intramural.htm HIPAA If you will be using, disclosing or accessing the health record (medical record, mental health or substance abuse records, etc.) for research purposes, then HIPAA applies. For more information on HIPAA authorization guidance see:  HYPERLINK "http://sjmhsmi.che.org/sjmaa/dept/IRB/Informed%20Consent%20and%20HIPAA%20Tools/GRID%20HIPAA%20Options%20for%20PIs%206-28-2016%20RC.pdf" http://sjmhsmi.che.org/sjmaa/dept/IRB/Informed%20Consent%20and%20HIPAA%20Tools/GRID%20HIPAA%20Options%20for%20PIs%206-28-2016%20RC.pdf HIPAA for the screening portion (do not re-describe screening process) Describe either: a) how HIPAA authorization will be obtained for the screening portion, who will obtain it; or b) the rationale for requesting a waiver of HIPAA authorization for the screening portion or c) whether a Decedents Information request is being made for all of the participants or d) the rationale for requesting a preparatory for research request for the screening portion. Note, the person extracting the information must be part of the SJMHS covered health entity and the data may not leave SJMHS. See IRB policy for more information:  HYPERLINK "http://www.stjoesannarbor.org/irb-policies-procedures" http://www.stjoesannarbor.org/irb-policies-procedures HIPAA for the intervention or chart review portion Describe either: a) how HIPAA authorization will be obtained and who will obtain it or b) the rationale for requesting a waiver of HIPAA authorization. or c) whether a Decedents Information request is being made for all of the participants or d) rationale for requesting a Limited Data Set with an accompanying Data Use Agreement in order to share data with an entity external to the SJMHS covered healthcare entity. You may also need to request a Business Associate Agreement between Trinity Health and the external entity. See IRB policy for more information:  HYPERLINK "http://www.stjoesannarbor.org/irb-policies-procedures" http://www.stjoesannarbor.org/irb-policies-procedures UNANTICIPATED PROBLEMS AND ADVERSE EVENTS Describe process for reporting any unanticipated problems and adverse events to the IRB under the SJMHS IRB policy. See the SJMHS Policies and Procedures for what is required to be reported:  HYPERLINK "http://www.stjoesannarbor.org/irb-policies-procedures" http://www.stjoesannarbor.org/irb-policies-procedures CONFLICTS OF INTERESTS Describe research team relationships with the sponsor/funding organization Assure that disclosures have been filed with the Research Compliance Department and that disclosures are fully explained. 11 Limitations and ASSUMPTIONS Describe any limitations to the study design, sample size, methods used, limited/narrow sample of population, tests used, etc. Include how extraneous variables will be controlled for or minimized. List any known assumptions that the research is operating under. 12 REFERENCES Provide references for the literature review and other citations made. Use the format used by your field (e.g., APA style, etc.). Appendices Consent form(s): if applicable Data collection tools Screening tools Surveys, interview questions, etc. Advertisements flyers, e-mails, videos, etc. Recruitment scripts All materials provided to participants Any other documents that you will be using to conduct the research     Your Title Here  PAGE 9 IRB Template version 1-21-2019 RESEARCH PROTOCOL - SJMHS MINIMAL RISK TEMPLATE  PAGE 1 *+4@ABIWXbc        ɾui]iuiuiQiuEh8B*\^Jphh"9B*\^Jphh=YB*\^JphhsB*\^JphhC/B*\^JphhC/hC/B*\^JphhC/5B*\^JphhBJ5>*B*\^Jph"hC/hC/5>*B*\^JphhC/h8B*phhC/hXB*phh=YB*ph hzh"95B*CJ aJ ph# *h} h"95B*CJ aJ ph+A  4MBgd4$a$?gdBJ?gd=4gd"9  ( B J ] ^ ; < > E Q ^ _ ` [ b c 45~~p~`~p~hBJh86B*\^JphhBJh.O0J'6\^JhBJhX0J'6\^JhBJhX6B*\^Jph(jhBJhX6B*U\^JphhBJhXB*\^JphhBJh8B*\^JphhXhX6B*\^JphhXhX5B*\^JphhXh86B*\^Jph%r}=>Jprs}m}^}mRm}Dh"95B*CJ aJ phhCh"90J'\^Jh"9h"9B*\^Jphjh"9B*U\^Jphh"9B*\^JphhBJhs5B*\^JphhBJB*\^Jphh.OB*\^JphhC/h8B*\^JphhX6B*\^JphhBJhX6B*\^Jph(jhBJhX6B*U\^JphhBJhX0J'6\^J  $ľyjyyd^XdLhBJ0JU6B*ph h R)0JY h80JY h40JYhBJh FB*CJaJphhBJh&jB*CJaJphhBJh%B*CJaJphhBJB*CJaJphh&j5CJ aJ h=Y5CJ aJ h85CJ aJ h80JU hX0JU hzh=5B*CJ aJ ph# *h"9h=5B*CJ aJ ph# *h"9h"95B*CJ aJ ph3@ABcdef'+⺴~tjte`[QDhBJhBJ5B*phhBJhBJ56 hBJ5 hz5 h45hBJh00JY5hBJhNC 0JY5hNC hNC 0JY hNC 0JYhBJh80JY5B*phhBJh80JYhBJhBJ0JY hBJ0JY h80JYh&jh46B*phh&jh"90JU6B*phh00JU6B*phh&jh40JU6B*phhBJh40JU6B*phBR.BU)gdBJ $ gdBJgdBJ4 $da$gd4dgd4gd4 02NOPQRSopqһݭңʖʆһsgʖhh80J'6]jhh8U h/j}hh8Ujhh8Uhh80J'6jhh8Uhh8OJQJ^JaJhh8jhh8U hh8h8h4h45 h4h4h4hz5# -./KLMNOY^rst̺Ӱ㒂ӡtӰdjkhh8Ujhh8Ujqhh8Uhh8 hq:0J'6hh8OJQJ^JaJhh80J'6jhh8Uh"9 hh8jhh8U h/jhh8Ujwhh8U'  !"<=>?@ABC_`abcnop٫Ҁٶpj_hh8Ujhh8U h/jehh8Uhh8hq:0J'6\^Jhh80J'6\^Jjhh8U hh8hh8OJQJ^JaJjhh8Ujhh8U(,3ɾسupi[OOFh&j0J'6\hh80J'6\jhh8U hh8 h/jYhh8Ujhh8Uhh8hhs0J'6\^Jh&j0J'6\^Jhq:0J'6\^Jh.O0J'6\^Jhh8OJQJ^JaJhh80J'6\^Jjhh8Ujhh8U345OPQRSTUVrstuv"#()*FGHIʻʴʝʍ~sl^sThh.s00J'6jMhh.s0U hh.s0jhh.s0U h.s0h.s0hBJh.s0h,)hh80J'6\h.s00J'6\jhh8U hh8hh8OJQJ^JaJjhh8U h/jShh8Ujhh8Uhh8 IJKbcd~ոȳȨ|uq|||fXfOh,)0J'6\jG hh8Ujhh8Uhq: hhz hh- hh hh8h,)hBJhh8OJQJ^JaJjhh.s0U h/jhh.s0Ujhh.s0Uhh.s0hh.s00J'6\hh.s0OJQJ^JaJ h.s00J'6A#U$If4gd.s0 $ gdBJgdBJ $ gdBJgd,)gdBJ $ ^`gdBJ@A}~!"#$%)3RĽȓȌК}vvnhh= hh.s0hh8OJQJ^JaJ hhc hhs hh=j hh8U hh8 hh- hhh.s0hq:hBJhh,)h,)5 h,)h,)hh8OJQJaJh,)jhh8U*RST[\xyz}slaVHh"9hz5CJ\aJh"95CJ\aJhhz5>*\ hhzhh80JU6hh80J^Jhh8OJQJ^JaJ h/j hh8Ujhh8Uhh8hh80J'6jA hh8U hh8jhh8U hh= h,)hh.s0WPkd $$Ifl0b$644 la$IfPkd; $$Ifl0b$644 laWPkd( $$Ifl0b$644 la$IfPkd $$Ifl0b$644 laWPkd $$Ifl0b$644 la$IfPkdw $$Ifl0b$644 laWPkdd $$Ifl0b$644 la$IfPkd $$Ifl0b$644 laWPkd$$Ifl0b$644 la$IfPkd $$Ifl0b$644 laWPkd$$Ifl0b$644 la$IfPkdQ$$Ifl0b$644 laWPkd>$$Ifl0b$644 la$IfPkd$$Ifl0b$644 laWPkd$$Ifl0b$644 la$IfPkd$$Ifl0b$644 laWPkdz$$Ifl0b$644 la$IfPkd+$$Ifl0b$644 la*+EFYZ $$Ifa$gd"9$IfPkd$$Ifl0b$644 la ()*+CDEFWXYZrs / ; @ [ \ { | òääزtmt hhG hh][CJOJQJ^JaJ hhGCJOJQJ^JaJhsCJOJQJ^JaJh2CJOJQJ^JaJ hhS3CJOJQJ^JaJ hh8CJOJQJ^JaJh"9 hh8 hZhZ hZhzhZh"9hz>* hhz&\ A!"+"G"w"""T & F8d7$8$H$^8`gdz$$a$T & F8d7$8$H$^8`gdz$a$@kd$$Ifl$h%644 laytA !!!@!A!O!W!!!""+"u""""""""""ͼ͵ziz]TH]T]zhh.4\^JaJ h.4\^JaJ hh8\^JaJ hhS3CJOJQJ^JaJ hh8CJOJQJ^JaJ hh8 hhdSh.4CJOJQJ^JaJhdSCJOJQJ^JaJ h.4h][ hhb CJOJQJ^JaJ hh}(CJOJQJ^JaJ hh][CJOJQJ^JaJ hh-CJOJQJ^JaJ"""""" #,#-#.#U#V#######"$0$=$H$Y$n$w$$޿︦ޘ{j\NhJCJOJQJ^JaJhsCJOJQJ^JaJ hh-CJOJQJ^JaJhh8\^JaJ hh.4CJOJQJ^JaJh.4CJOJQJ^JaJ#hh85CJOJQJ^JaJ hh%q= hh}(CJOJQJ^JaJh.OCJOJQJ^JaJ hh8CJOJQJ^JaJ hh%q=CJOJQJ^JaJ" #.#V##"$0$$$$5%*&T&m'T & F(8d7$8$H$^8gd_T & F8d7$8$H$^8gdz$$a$T 88d7$8$H$^8gdzT & F 88d7$8$H$^8`gdzT & F 88d7$8$H$^8gdz $$$$$$$$$$$$$$$$%%%%2%3%4%6%B%L%]%k%u%%´£’vhZvhhh:CJOJQJ^JaJh.4CJOJQJ^JaJh2CJOJQJ^JaJh[^CJOJQJ^JaJ hh.4CJOJQJ^JaJ hhVCJOJQJ^JaJh.OCJOJQJ^JaJ hh8CJOJQJ^JaJ hh-CJOJQJ^JaJhJCJOJQJ^JaJhr}CJOJQJ^JaJ%%%%%%%%%%'&*&,&7&B&J&S&T&&&& ' 'ŴţŗyhVGh9h_CJOJQJ^JaJh_5CJOJQJ^JaJ#h_h_5CJOJQJ^JaJ hh_CJOJQJ^JaJhhJ\^JaJ h.4\^JaJ h.O\^JaJ hh8\^JaJ hh%q=CJOJQJ^JaJ hh} CJOJQJ^JaJ hh8CJOJQJ^JaJh[^CJOJQJ^JaJh.4CJOJQJ^JaJh0CJOJQJ^JaJ 'l'''+(A(D(O(Y((((()z)))))))ܽ|n|]L;; h[^h_CJOJQJ^JaJ hTh_CJOJQJ^JaJ h[Rh_CJOJQJ^JaJhJCJOJQJ^JaJ hhq #CJOJQJ^JaJh_CJOJQJ^JaJ hhVCJOJQJ^JaJ hh-CJOJQJ^JaJ hh8CJOJQJ^JaJh'7CJOJQJ^JaJ hh_CJOJQJ^JaJ#hd#h_5CJOJQJ^JaJm'+(()))*Q++ --?/Z/$$a$T & F8d7$8$H$^8`gd[RT & F8d7$8$H$^8gdzT & F8d7$8$H$^8`gdd#T & F8d7$8$H$^8`gdzT & F(8d7$8$H$^8gdd# ))P*Q*S*******@+O+Q+++++,@,X,ϽϽ|kZI;ZIZhgn:CJOJQJ^JaJ hh|(CJOJQJ^JaJ hh&+CJOJQJ^JaJ hh-CJOJQJ^JaJh_CJOJQJ^JaJ#hd#h_5CJOJQJ^JaJh_5CJOJQJ^JaJ#hd#h|5CJOJQJ^JaJ#hd#h-5CJOJQJ^JaJ#hd#hgn:5CJOJQJ^JaJ hh8CJOJQJ^JaJh.OCJOJQJ^JaJX,d,,,,,,,, - -----.. ......//?/R/Y/Z/ͼͼͼͼͼͼxjbZbhhS3\hh8\h[RCJOJQJ^JaJ h[Rh[RCJOJQJ^JaJ#hd#hz5CJOJQJ^JaJ#hd#h_5CJOJQJ^JaJh_5CJOJQJ^JaJ hhzCJOJQJ^JaJ hh|(CJOJQJ^JaJ hh&+CJOJQJ^JaJ hh/pCJOJQJ^JaJZ/s///00I0J0000001112.2B2[2333´veWF hh[^CJOJQJ^JaJhhZCJOJQJ^JaJ hhhZCJOJQJ^JaJh=CJOJQJ^JaJ hhKCJOJQJ^JaJ hhgn:CJOJQJ^JaJh'7CJOJQJ^JaJhgn:CJOJQJ^JaJhS3CJOJQJ^JaJh.OCJOJQJ^JaJ hhS3CJOJQJ^JaJ hh8CJOJQJ^JaJZ/J0011112[2333E4444hd7$8$H$^hgd.OT 88d7$8$H$^8gdM,T & F 8d7$8$H$`gdM,T & F 88d7$8$H$^8`gd[^T & F 88d7$8$H$^8`gdz3D4E4]4^4444444 5 555555 5$5%525пб|l_R_RE_R_l8hh8CJOJQJhd#5B*\]phh5B*\]phh F5B*\]phhh85B*\]phh.O5B*\]phhh8^JaJhh85^JaJ hhM,CJOJQJ^JaJhzCJOJQJ^JaJ hh/?CJOJQJ^JaJ hhUQ.CJOJQJ^JaJh[^CJOJQJ^JaJ h h[^CJOJQJ^JaJ44%5M55526i666888q( # 0 P@80d1$7$8$H$^8`0gdzT8d7$8$H$^8`gdzTd7$8$H$gdT8d7$8$H$^8gd?'T & F8d7$8$H$^8gdz d7$8$H$gd.O 8d7$8$H$^8 25;5<5>566666687=7N7\7g7h7777c8d8888888889999S:ĹĬ颬~vnf_[_[_W_h,ah.O hh8hh85hhz5hh5hhNC CJOJQJh,aCJOJQJhNC h?'CJOJQJhNC CJOJQJhNC hNC CJOJQJh,a5CJOJQJh?'hNC 5CJOJQJh8CJOJQJhh8CJOJQJh?'CJOJQJhh?'CJOJQJ!8Q99S:s:;V;;A<B<v8d7$8$H$^8gdz & F 8d7$8$H$^8gdzhd7$8$H$`hgd.O- & F # 08 P@8dd1$7$8$H$[$\$^8gdz( & F # 08 P@8d1$7$8$H$^8gdz S:s:;;;<@<B<C<E<]<<==S======>{>>>>>>>>??/?9?:?K?L???@@@-@N@@宧֑un hhhZhh%q=0J'6jhh%q=U hh>dAhh85 hhV hhR! hh#;ahM,hh85B*\]ph hhhh'@5 hM,5hh5 hh|( hh8 hh%q=hh85B*ph+B<]<==S={==|>>>}md7$8$H$^gd & F8d7$8$H$^8gd R) & F8d7$8$H$^8gdzhd7$8$H$`hgd.O d7$8$H$` & F8d7$8$H$^8gdz( # 0 P@80d1$7$8$H$^8`0gdz >?@@@@oH' & 0` P@`1$7$8$H$^``gd.O & 0` P@`1$7$8$H$^`% & F # 08 P@81$7$8$H$^8gdz) & F% # 0` P@81$7$8$H$]^8gdz! # 0` P@1$7$8$H$]gdd#@@@wDDDDE%E.EEEEEEEEE,F-F.FtFFFzfPff<'hhKCJOJPJQJ\^JaJ*hh85CJOJPJQJ\^JaJ'hh8CJOJPJQJ\^JaJ#hh85CJOJQJ^JaJ hhsCJOJQJ^JaJ hh8CJOJQJ^JaJh.Oh85B*ph h.O5 hh hhKhh'@5 h5h.O hh8hh85B*phhhz5B*ph@^AAAABTBBBC1CzC}}}}}}}0 & F & 0 P@ddd1$7$8$H$[$\$^gd8% & F & 0` P@d1$7$8$H$gd8+ & F ) 08` P@8d1$7$8$H$^8gdz zC)DDDEE}P- & F & 0`p P@dd1$7$8$H$\$^gd8$ # 0 P@d1$7$8$H$^gd'@- & F 0 P@ddd1$7$8$H$[$\$^gd8/ & F # 0 P@ddd1$7$8$H$[$\$^gd8EEE.FtFFFGvGyGGd[ $$a$gd1M ) 0` P@1$7$8$H$gd1&, & F ) 0` P@1$7$8$H$^`gdM, & 0` P@1$7$8$H$gd$zcT & F^`gd8 & h` P@1$7$8$H$gd.O FFFFFFFFFG0GQGuGvGxGyGzGGGGGGGծ릞|tlcUGh.Ohz5CJ\aJh.Oh1M5CJ\aJh.OCJ\aJhh1M\hh8\ h.s0\hh85 hh8 hh1M hh$zchh$zc5hhz5$h,a5CJOJPJQJ\^JaJ'hh1MCJOJPJQJ\^JaJ*hh85CJOJPJQJ\^JaJ'hh8CJOJPJQJ\^JaJGG IiJ{J8KKLLL`MNOmO~ & F^`gd~sT & Fd7$8$H$^`gdF$$*^*`a$gd1&- & F ^`gd1&- & F^`gd1Mgd1&  & F`gd1&  & F^gdgd GGHH&H'H)H9H;HWHZH I IISIIIIiJlJoJ{JJJJJK8KMKKKLLLLùùß||pïd_WhhF\ h.s0\hh1M0JU6]hd#h1M0JU6>*hhUQ.0JU6hh1M0JU6>*h.O0JU56CJaJhh1M0JU56CJaJhhF0JU6hhG0JU6hh1M0JU6hh~s0JU6h~sh~s0JU6 h~s0JU6hh80JU6h.Oh5CJ\aJ"LM M#MIMJMUM^M_M`MMMM:NCNxNNNNN O OO4O@OAOTOŗŅŶymaVNFNhM,^JaJh;1^JaJh R)h R)^JaJhFCJOJQJ^Jh;1CJOJQJ^Jh R)CJOJQJ^J#hd#h~s5CJOJQJ^JaJhd#CJOJQJ^JaJ hh(CJOJQJ^JaJhhFCJOJQJ^Jh~sCJOJQJ^JaJh;1CJOJQJ^JaJh R)CJOJQJ^JaJ hhFCJOJQJ^JaJTO]O^ObOjOmOPlP{P~PPPPQQQQoQudVdH7 h R)h R)CJOJQJ^JaJhFCJOJQJ^JaJh R)CJOJQJ^JaJ hhFCJOJQJ^JaJhhF>*CJOJQJ^J hhM,CJOJQJ^JaJ*hM,hF0JU6CJOJQJ]^JaJ'hh(0JU6CJOJQJ^JaJ'hhF0JU6CJOJQJ^JaJ h R)h~sCJOJQJ^JaJh R)h R)^JaJh;1^JaJh R)^JaJmOPPPPQoQRRs_T & Fd7$8$H$^gd~sTd7$8$H$^`gdM,T & Fd7$8$H$^`gdFT 88d7$8$H$^8gd1&T 8d7$8$H$^gdM,T & F 8d7$8$H$^gd1&T & Fd7$8$H$^`gd~soQpQkRRRRRRRRRRRRHSISKSSS[SjSkSxSSSSSFTUT^TgThTjTTTͿͿͿͿޮ{q{g{g]V]{g h7u10JU6hh7u10JU6hh(0JU6hhR!0JU6hhF0JU6hh80JU6hhJ\hhR!\hh7u1\ hh8 hh R)CJOJQJ^JaJh?'CJOJQJ^JaJ hM,h?'CJOJQJ^JaJ hM,hM,CJOJQJ^JaJ h U7hM,CJ$OJQJ^JaJ!RISkSTUUUVW1WIWJWjWkWT8d7$8$H$^8gdT & F8d7$8$H$^8gdBJTd7$8$H$gd($ hdh7$8$H$a$gd$$a$- & F h^gd8 $$a$gd/pTd7$8$H$^gd?' TTTTUU UU'U2U=UBUQUUUUU,VcVfVVVVVVVVVVVWWWWW0W1W׷סח׋|rh^hh85aJ hh8\aJ hh.s05aJ h.s0aJ hh.s0aJ hhs0JU6]hh(0JU6hh/p0JU6hh80JU6]hh}(0JU6hh][0JU6hh}(0JU6]hhs0JU6hh80JU6hhR!0JU6hhF0JU6$1W6W7WGWIWJWiWjWkWtWzW|W}WWWȶmYH6H#hhX5CJOJQJ^JaJ hhXCJOJQJ^JaJ&hhX5>*CJOJQJ^JaJ&hhzE 5>*CJOJQJ^JaJ&hh85>*CJOJQJ^JaJ#hh5CJOJQJ^JaJh(5CJOJQJ^JaJ#hh(5CJOJQJ^JaJ#hh(>*CJOJQJ^JaJhh8^JaJhhH0Jhh80JhhZ0JkW|W*X0XXXX6Y@ZZ[\\]T & Fd7$8$H$gd8T & F7$8$H$^gd~sT & F ^gd~sTh7$8$H$`hgdBJT7$8$H$^`gd1&Td7$8$H$^`gd(Thd7$8$H$`hgdBJ WWW XXX!X(X)X*X+X-X.X/X0X1X3X4XRX^XeX}X~XXXXXͻͪޙͅs͙dsdͪR#hh(5CJOJQJ^JaJh5CJOJQJ^JaJ#hhzE 5CJOJQJ^JaJ&hhzE 5>*CJOJQJ^JaJ hhXCJOJQJ^JaJ hhR!CJOJQJ^JaJ#hhzE >*CJOJQJ^JaJ hhzE CJOJQJ^JaJ hhq #CJOJQJ^JaJ hh8CJOJQJ^JaJXXXCYDY@ZZ[\H]]]]]^^^__`\```DaOaaa'b2b@bHbQbбpbbbbbbQ hhn0CJOJQJ^JaJh.OCJOJQJ^JaJ hhXCJOJQJ^JaJh8CJOJQJ^JaJ hhq #CJOJQJ^JaJ hhR!CJOJQJ^JaJ hh8CJOJQJ^JaJh~sCJOJQJ^JaJ h~sh[RCJOJQJ^JaJh(CJOJQJ^JaJ hh(CJOJQJ^JaJ]]1^a^^^ _z_`\``abbccdudee/fT & Fd7$8$H$gd8Td7$8$H$^T & Fddd[$\$gd8T & Fd7$8$H$gd8Qb\bbbQc\cccd d5d@ddde e}eeeefff.f/fBfCfTf_fbfjfg"g*gEgFgXg{gựqbh U7hKCJOJQJ^Jh U7hHCJOJQJ^Jh U7hZCJOJQJ^J hh/?CJOJQJ^JaJ hhZCJOJQJ^JaJhh8;\hhH;\h R)CJOJQJ^JaJhdSCJOJQJ^JaJ hh8CJOJQJ^JaJh.OCJOJQJ^JaJ%/fCf~ff"j(jjj-l.lulllllT8d7$8$H$^8`gdBJT & F#Fd7$8$H$^Fgd1&# & 0` P@1$7$8$H$^gd1& ^gd1&^gdT & Fd7$8$H$gdHT & Fd7$8$H$gd8 $^a$gd {ghhKhWhbhch^i_i~iiiii j!j"j(jjjjkkkk+l,l.lNltl̮̠̾uuku\Nhh6OJQJ^Jh5CJOJQJ^JaJhh!0J'6jhh!U hh!h7u1 hhhZhhhZ;\^JaJhhMzOJQJ\^Jhh/?0J'6CJ\^Jhh/?OJQJ\^J$jhh/?OJQJU\^Jh U7h/?CJOJQJ\^Jh U7hZCJOJQJ\^JtlullllllllllllDmEmHmImKmȶkWE3#hh!5CJOJQJ^JaJ#hh!6CJOJQJ^JaJ&hh!56CJOJQJ^JaJ&hhhZ56CJOJQJ^JaJ&hh56CJOJQJ^JaJ#hhhZ>*CJOJQJ^JaJ hhhZCJOJQJ^JaJ#hh5CJOJQJ^JaJ hhZ5>*CJOJQJ^JaJ&hhhZ5>*CJOJQJ^JaJ#hhhZ5CJOJQJ^JaJlllDmImmm o!oUoVogohooooT8d7$8$H$^8`gdBJTFd7$8$H$^FgdT & F#Fd7$8$H$^Fgd1&T8d7$8$H$^8gd1&T7$8$H$^`gd1&Td7$8$H$^`gd1&Kmmmmmmnnnnoo o!o0o;oKoToUo̺sdRdRChhZ5CJOJQJ^JaJ#hhhZ5CJOJQJ^JaJh5CJOJQJ^JaJ#hhhZ>*CJOJQJ^JaJhh!0J'6^JaJ)jhh!CJOJQJU^JaJ#hh!5CJOJQJ^JaJ#hh!6CJOJQJ^JaJ&hh!56CJOJQJ^JaJh5CJOJQJ^JaJ hh!CJOJQJ^JaJUoVofogohojoooooooooooooooooȴn]K]nC;4 hh!hh!5hh5#hhhZ5CJOJQJ^JaJ hhhZCJOJQJ^JaJ hh!CJOJQJ^JaJ#hh!>*CJOJQJ^JaJ hhhZCJOJQJ^JaJ#hhhZ5CJOJQJ^JaJ&hh5>*CJOJQJ^JaJ hhZ5>*CJOJQJ^JaJ&hhhZ5>*CJOJQJ^JaJ#hh5CJOJQJ^JaJooPpTprw?wAwBwDwEwWwXwYw[wwwwww $d $ $da$ $ !a$ !$7gd $dgd- - & F'gdEwTwVwWwXwYw[w\wbwcwdwewlwwwwwwwwwwwwwwwwxxxx x x x x xxɴɬۂ}x}x}pɴɇlf h80JPhS9h8CJaJ hBJ>* h8>* h=Y>* h8CJhkNw0J*CJaJhj&'hj&'0J*CJaJhkNw0J*CJhj&'0J*CJh0J*CJmHnHuh80J*CJjh80J*CJU h8CJh8 hhhhCJ h"9CJ *h"9h"9CJ%wwx x x xx $ !a$ !$6 00&PBP/ =!"#$%` 30&PBP/ =!"#$%` 70&P1hBP/ =!"#$%` }DyK _Toc243298795}DyK _Toc243298795}DyK _Toc243298797}DyK _Toc243298797}DyK _Toc243298798}DyK _Toc243298798}DyK _Toc243298799}DyK _Toc243298799}DyK _Toc243298800}DyK _Toc243298800}DyK _Toc243298801}DyK _Toc243298801}DyK _Toc243298802}DyK _Toc243298802}DyK _Toc243298803}DyK _Toc243298803}DyK _Toc243298805}DyK _Toc243298808}DyK _Toc243298808}DyK _Toc243298810}DyK _Toc243298812}DyK _Toc243298813}DyK _Toc243298813M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55M$$If!vh#v#v:V l6,55E$$If!vh#vh%:V l6,5h%ytA^] 666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH J`J NormaldCJOJQJ_HmH sH tH L@L  Heading 1$$hh@&a$ 5;CJ J@J  Heading 2$h@&a$ 5;CJL@!L  Heading 3$@&^`8a$CJ D@1D  Heading 4$@&`0;CJJ@AJ  Heading 5 M@&^E`CJL@L  Heading 6$h@&^`]5<@<  Heading 7$@&5CJ@@@  Heading 8 $x@&5CJ@ @@  Heading 9 $@&a$5CJDA D Default Paragraph FontVi@V 0 Table Normal :V 44 la (k ( 0No List VoV Heading 1 Char"5CJ KH OJPJQJ\^JaJ ZoZ Heading 2 Char&5;CJOJQJ^J_HmH sH tH RoR Heading 3 Char5CJOJPJQJ\^JaJRo!R Heading 4 Char5CJOJPJQJ\^JaJXo1X Heading 5 Char$56CJOJPJQJ\]^JaJJoAJ Heading 6 Char5OJPJQJ\^JLoQL Heading 7 CharCJOJPJQJ^JaJRoaR Heading 8 Char6CJOJPJQJ]^JaJDoqD Heading 9 CharOJPJQJ^J2B@2  Body TextDoD Body Text CharCJOJQJ^JHP@H  Body Text 2 ^ B*CJphHoH Body Text 2 CharCJOJQJaJR@R.s0TOC 1 $ ^`^JmHnHuR@RBJTOC 2 $ 0^`0aJmHnHuJ@JTOC 3$ ]h^`0 mHnHuF@FTOC 4 $ ^ `| mHnHu8 @8 Footer !CJ>o>  Footer CharCJOJQJaJ:@:TOC 5 "$ mHnHu** TOC 6#^** TOC 7$^** TOC 8%^x** TOC 9&^@JU`qJ  Hyperlink6>*B*CJOJQJ^JphFQ@F  Body Text 3(x^^JHoH Body Text 3 CharCJOJQJaJ2)`2  Page Number^JNN SchemaBullet1+<P^`PFOF SchemaTxt,p^p`CJ\POP Bullet (listing)-x^h`N6@N  List Bullet 2.x8^8`CJTT Bullet (listing)2/< 8^h88 List Number20^hNN List Number2a1x^`JO"J ListNumber12xh^h`CJROR Section 3dhh^h` 5;CJ HOBH SchemaTitle 4a$ 5;aJVORV Bullet (listing)35x8^8`^J4O4 Appendix6CJ^J4@r4 Header 7!>o>  Header CharCJOJQJaJ>@>  Comment Text9dCJFoF Comment Text Char OJQJ^JJV`J FollowedHyperlink>*B* ^Jph66 Body Text 4<^H@H  Balloon Text=CJOJQJ^JaJBoB Balloon Text CharCJaJ<>@< Title?dxa$aJNoN Title Char"5CJ KHOJPJQJ\^JaJ `O` Body Text 2 + Italic,BlackA6B*]phVO"V Instructional TextBd6B*]ph>J@2> Subtitle Cda$OJQJJoAJ Subtitle CharCJOJPJQJ^JaJHRH List Bullet 2aE 8^@oa@ Char CJOJQJ^J_HmH sH tH F'`qF Comment Reference CJ^JaJFj@F Comment SubjectHd5\ZoZ Comment Subject Char5CJOJQJ\^JaJX^@X  Normal (Web)Jd dd[$\$CJOJQJaJ4a`4  HTML Cite 6]^JBOB Style1Ldx OJQJaJROR Style Body Text + ItalicM6]o %Style Hyperlink + Italic No underline"6>*B*CJOJQJ]^Jph:r: Style Hyperlink +6o6 Style 10 ptCJ^JPOP Style SchemaTxt + BoldQ5CJZO"Z Style Body Text 2 + ItalicR 6CJ]>OA2> Style Heading 4S\Z@BZ List ParagraphTd^m$CJOJQJaJ2X`Q2 Emphasis 6]^JFObF Emphasis+StrongV 56\]LOrL Emphasis+HyperlinkW 6B*ph\o\ Emphasis+Strong Char56CJOJQJ\]^J.W`. Strong 5\^JH@H  Footnote TextZd CJOJQJLoL Footnote Text CharOJPJQJ^JD&`D Footnote ReferenceH*^JPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] np8m  3IR "$% ')X,Z/325S:@FGLTOoQT1WWXQb{gtlKmUooruEwx=?@ABDEFGHIKLWYZ\]^`abdfhkoqrsuwxz{}B"m'Z/48B<>@zCEGmORkW]/floWtvwx>CJMNOPQRSTUVX[_cegijlmnptvy|~];_b4= r 01NPRp.Ls!=?@B`o4PRSUs)Gc![yK778aa bcc+dffgiijj?kukpXXXXX XX%X%X%X%X%X%X%X%̕XX%̕XXX%̕̕XXXXXX")+!!L# @0(  B S  ?6 OLE_LINK1 OLE_LINK2 _Toc58818890 _Toc60193103 _Toc60195133 _Toc60200981 _Toc224445192 _Toc35168723 _Toc224445193 _Toc243298795 _Hlt433099344 _Hlt433099060 _Hlt433099081 _Hlt433099110 _Hlt433099172 _Toc224445195 _Toc243298797 _Toc42588959 _Toc53202800 _Toc224445198 _Toc243298798 _Toc42588964 _Toc53202805 _Ref102891403 _Toc224445204 _Toc243298799 _Toc224445205 _Toc243298800 _Toc243298801 _Toc243298802 _Toc42588965 _Toc53202806 _Toc224445209 _Toc243298803 _Toc42588970 _Toc53202811 _Toc42588975 _Toc53202823 _Toc224445231 _Toc243298805 _Ref102891490 _Toc224445238 _Toc243298806 _Toc42588991 _Toc53202844 _Toc224445244 _Toc243298807 _Toc243298808 _Toc243298809 _Toc243298811 _Toc243298812 QuickMark _Toc224445291 _Toc243298813AA [[[[ "*?'?'?'?'y?y?y?y?y?y?IKIKIKNNNNO1O"bjnnnp @ @ @ @@ !&'"#$%()*+,-./012345      */B?'A'A'A'R'{?{?{??KKKKKKKKKKOOOO0O7O9jmnn!np9o;oo?oAoBoDoEo pp=   ' ' + s!@o334STTc68>@wy{}NNST/;@||2346BL[ [ !!(( ------- -..g/h/c0d011"7"7F8F8::::<<>>>>y?y?CCKKKKIOIOiOjO0P1P3P4P"b"b.dtdddddDeEeee!g0g;gKgTgUgfggghghgggPhQhWlWl8o9o9o@wy{}NNST/;@||2346BL[ [ !!(( ------- -..g/h/c0d011"7"7F8F8::::<<>>>>y?y?CCKKKKIOIOiOjO0P1P3P4P"b"b.dtdddddDeEeee!g0g;gKgTgUgfggghghgggPhQhWlWl8o9oEoYo[oeoooooooooooop pp(R! K `Gvv NJ  U*Fx$roUu K8L [ {,Q/jbVV k Y da|z'0/Wf d d"J_0(NQ0"2#4=m"3~08Ba89p01!>Ld C dDйܘM/D(C?F,ORF"`J1NQD6jNA[n<^ dJ+cf[B }fAftJXhl%Gi zoqZ%Cr([t$x5~nh^`OJQJo(hHh~ ^~ `OJQJ^Jo(hHohN ^N `OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^^^`OJQJ^Jo(hHoh.^.`OJQJo(hH ^`OJQJo("  ^`OJQJo("  pp^p`OJQJo(- @ @ ^@ `OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  PP^P`OJQJo(" hi^i`OJQJo(hHh9 ^9 `OJQJ^Jo(hHoh ^ `OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohy^y`OJQJo(hHhI^I`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHhh^h`CJOJQJo(h?^`?OJQJo(hH?^`?^Jo(.x0^x`0^Jo(..H 0^H `0^Jo(... ^`^Jo( .... P^P`^Jo( ..... `^``^Jo( ...... X`^X``^Jo(....... ^`^Jo(........ ^`OJQJo(hp^p`OJQJo(hH @ ^@ `OJQJo( ^`OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(P^P`OJQJ^Jo(o  ^ `OJQJo(h0^0`OJQJo(hHh ^ `OJQJ^Jo(hHoh ^ `OJQJo(hHh^`OJQJo(hHhp^p`OJQJ^Jo(hHoh@^@`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJQJo(hH ^`OJQJo(p^p`OJQJ^Jo(o @ ^@ `OJQJo( ^`OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(P^P`OJQJ^Jo(o  ^ `OJQJo( ^ `o()  ^ `hH. L^`LhH. p^p`hH. @^@`hH. L^`LhH. ^`hH. ^`hH. L^`LhH. ?^`?OJQJo(?^`?^Jo(.x0^x`0^Jo(..H 0^H `0^Jo(... ^`^Jo( .... P^P`^Jo( ..... `^``^Jo( ...... X`^X``^Jo(....... ^`^Jo(........ ^`OJQJo(^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo(h ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH. ?^`?OJQJo(?^`?^Jo(.x0^x`0^Jo(..H 0^H `0^Jo(... ^`^Jo( .... P^P`^Jo( ..... `^``^Jo( ...... X`^X``^Jo(....... ^`^Jo(........h^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJQJo(hHh ^`hH.h ^`hH.h  L^ `LhH.h j^j`hH.h :^:`hH.h  L^ `LhH.h ^`hH.h ^`hH.h zL^z`LhH. ^`OJQJo("  ^`OJQJo("  pp^p`OJQJo("  @ @ ^@ `OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  PP^P`OJQJo("  ^`OJQJo( p^p`OJQJo(o @ ^@ `OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( P^P`OJQJo(o  ^ `OJQJo( ^`OJQJo(p^p`OJQJ^Jo(o @ ^@ `OJQJo( ^`OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(P^P`OJQJ^Jo(o  ^ `OJQJo(h^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJQJo(hH ^`OJQJo(p^p`OJQJ^Jo(o @ ^@ `OJQJo( ^`OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(P^P`OJQJ^Jo(o  ^ `OJQJo( ?^`?OJQJo(?^`?^Jo(.x0^x`0^Jo(..H 0^H `0^Jo(... ^`^Jo( .... P^P`^Jo( ..... `^``^Jo( ...... X`^X``^Jo(....... ^`^Jo(........h^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh ^ `OJQJ^Jo(hHoh ^ `OJQJo(hHhx^x`OJQJo(hHhH^H`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hH ^`OJQJo(^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo( ?^`?OJQJo(h?^`?OJQJo(hHx0^x`0^Jo(..H 0^H `0^Jo(... ^`^Jo( .... P^P`^Jo( ..... `^``^Jo( ...... X`^X``^Jo(....... ^`^Jo(........hx^x`OJQJo(hHhH ^H `OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHhX^X`OJQJo(hHh(^(`OJQJ^Jo(hHoh^`OJQJo(hH ^`OJQJo( p^p`OJQJo(o @ ^@ `OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( P^P`OJQJo(o  ^ `OJQJo(P^P`5o()  ^ `hH.  L^ `LhH. ^`hH. ^`hH. `L^``LhH. 0^0`hH. ^`hH. L^`LhH. ^`OJQJo(^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo( ?^`?OJQJo(?^`?^Jo(.x0^x`0^Jo(..H 0^H `0^Jo(... ^`^Jo( .... P^P`^Jo( ..... `^``^Jo( ...... X`^X``^Jo(....... ^`^Jo(........h^`OJQJo(hH p^p`OJQJo(o @ ^@ `OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( P^P`OJQJo(o  ^ `OJQJo(h^`OJQJo(hHhp^p`OJQJ^Jo(hHoh@ ^@ `OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHhP^P`OJQJ^Jo(hHoh ^ `OJQJo(hH ^`OJQJo( p^p`OJQJo(o @ ^@ `OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( P^P`OJQJo(o  ^ `OJQJo( @^@`OJQJo(^`OJQJ^Jo(o  ^ `OJQJo(  ^ `OJQJo(^`OJQJ^Jo(o P^P`OJQJo(  ^ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo("  ^`OJQJo("  pp^p`OJQJo(- @ @ ^@ `OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  PP^P`OJQJo(" h^`OJQJo(hH p^p`OJQJo(o @ ^@ `OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( P^P`OJQJo(o  ^ `OJQJo(h ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH.h?^`?OJQJ^Jo(hHo?^`?^Jo(.x0^x`0^Jo(..H 0^H `0^Jo(... ^`^Jo( .... P^P`^Jo( ..... `^``^Jo( ...... X`^X``^Jo(....... ^`^Jo(........hH ^H `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohX^X`OJQJo(hHh(^(`OJQJo(hHh^`OJQJ^Jo(hHoh!^!`OJQJo(hH( U*Wf 2d Cn<^J+cqf1NA[JXh1!>=m"3aC?FQ/M/Dr+Uu d"DBa89vv 6jNVV `JRF[t_0L [ GiNQ0Cr Yx5~R!'0B }f((         ψPqbSpȞ̳Z>b*3m8E(Xa                                              .C<                                             ut>Tv4֐B-vh"^                                                                                   x                                                     $LXoD!&d2 F@j쳘Fy'V                            -#`d8 #`5#-{5#`/~g)5Vs75V-?5VNF5#`8QJ##s_NmSjcG\#`ZYjcG\#`jcG\bjcG\#`F;i#`k5V?hzjcG\#`X5|jcG\#`.4 a NC p "=k1Mn05F~s=AszE b R!q #?'j&'|(,)) R)&+ML+8,M,1-UQ..s0;17u12567 U78"9q:gn:%q=/?'@\A>dA1BcCH+IBJSOdSVX=YhZk[,a#;a$zcd/ppMsEpukNw+U|6}r}9~!73[4-|s^Pc`G/.O2Z{d#a6^ S35[Z _=} 1&KR0FhG?J[Rc<&jC/Kz FJKV]['7=S9+".:ATh/X(9}(ZzMz%[^~ATn9o;o@ e e e ep@Unknown G*Ax Times New Roman5Symbol3. *Cx Arial7.@Calibri7@Cambria5. .[`)Tahoma7. [ @Verdana?= *Cx Courier New;WingdingsA$BCambria Math"hT'LqGTG ^8^8!oo KqHX  $P[2! xx NIDCR Protocol TemplateThis document is the National Institutes of Dental and Craniofacial Research (NIDCR) Clinical Protocol (protocol) template, which is required for developing NIDCR-funded clinical research protocols that utilize an intervention.NIDCR, template, intervention, clinical trial, principal investigator, signature, site investigator, protocol summary, schematic of study design,NIDCRRozelle Copeland(                           ! " # $ % & ' Oh+'0P` |    NIDCR Protocol TemplateThis document is the National Institutes of Dental and Craniofacial Research (NIDCR) Clinical Protocol (protocol) template, which is required for developing NIDCR-funded clinical research protocols that utilize an intervention.NIDCRNIDCR, template, intervention, clinical trial, principal investigator, signature, site investigator, protocol summary, schematic of study design,NormalRozelle Copeland12Microsoft Office Word@@ @y@p\^՜.+,D՜.+,d  hp  $Michigan Peer Review Organization8o NIDCR Protocol Template Titlel (X``  _PID_HLINKS_NewReviewCycleA i6http://www.stjoesannarbor.org/irb-policies-proceduresf6http://www.stjoesannarbor.org/irb-policies-proceduresc6http://www.stjoesannarbor.org/irb-policies-procedures%,`shttp://sjmhsmi.che.org/sjmaa/dept/IRB/Informed Consent and HIPAA Tools/GRID HIPAA Options for PIs 6-28-2016 RC.pdfJo]=https://grants.nih.gov/grants/policy/coc/appl_intramural.htmTXZZhttp://sjmhsmi.che.org/sjmaa/dept/IRB/Informed Consent and HIPAA Tools/Forms/Library.aspx0S_Toc2432988130P_Toc2432988120M_Toc2432988100G_Toc2432988080D_Toc2432988050>_Toc24329880308_Toc24329880202_Toc2432988010,_Toc243298800?&_Toc243298799? _Toc243298798?_Toc243298797?_Toc243298795?_Toc243298794&# 'http://www.stjoesannarbor.org/IRBForms\ jhttp://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=56.110&SearchTerm=minimal%20risk<http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html46.110<http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html46.102h>hhttp://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=50.3&SearchTerm=minimal%20risk  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry F7\ Data _1TableWordDocumentSummaryInformation(DocumentSummaryInformation8CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q